Skip to main content

Table 7 Parameters for evaluating the anti-amastigote activity of larval products on peritoneal macrophages infected with Leishmania major

From: The therapeutic effect of larval saliva and hemolymph of Lucilia sericata on the treatment of Leishmania major lesion in BALB/c mice946

Treatment

Dosages (ug/mL)

PL

SVI

72 Hrs

120Hrs

72 Hrs

120 Hrs

No-treatment control

0

2.34 ± 0.65

2.97 ± 0.34

172.45 ± 9.3

201.8 ± 8.1

Saliva

150

2.07 ± 0.61

1.99 ± 0.48

135.3 ± 8.8

69.65 ± 6.9

450

2.01 ± 0.47

1.81 ± 0.66

105.9 ± 6.9

50.68 ± 5.3

Hemolymph

150

2.00 ± 0.80

1.76 ± 0.42

118.6 ± 5.1

59.40 ± 7.7

450

1.85 ± 0.25

1.35 ± 0.57

77.19 ± 7.8

47.73 ± 4.4

Positive control-Glucantime

50

1.91 ± 0.48

1.41 ± 0.48

97.07 ± 5.7

41.04 ± 5.5

100

1.79 ± 0.36

1.33 ± 0.39

68.48 ± 3.5

21.82 ± 3.1

  1. PL parasite load, SVI survival index